A multi-omic landscape of steatosis-to-NASH progression

Abstract

Nonalcoholic steatohepatitis (NASH) has emerged as a major cause of liver failure and hepatocellular carcinoma. Investigation into the molecular mechanisms that underlie steatosis-to-NASH progression is key to understanding the development of NASH pathophysiology. Here, we present comprehensive multi-omic profiles of preclinical animal models to identify genes, non-coding RNAs, proteins, and plasma metabolites involved in this progression. In particular, by transcriptomics analysis, we identified Growth Differentiation Factor 3 (GDF3) as a candidate noninvasive biomarker in NASH. Plasma GDF3 levels are associated with hepatic pathological features in patients with NASH, and differences in these levels provide a high diagnostic accuracy of NASH diagnosis (AUROC = 0.90; 95% confidence interval: 0.85−0.95) with a good sensitivity (90.7%) and specificity (86.4%). In addition, by developing integrated proteomic-metabolomic datasets and performing a subsequent pharmacological intervention in a mouse model of NASH, we show that ferroptosis may be a potential target to treat NASH. Moreover, by using competing endogenous RNAs network analysis, we found that several miRNAs, including miR-582-5p and miR-292a-3p, and lncRNAs, including XLOC-085738 and XLOC-041531, are associated with steatosis-to-NASH progression. Collectively, our data provide a valuable resource into the molecular characterization of NASH progression, leading to the novel insight that GDF3 may be a potential noninvasive diagnostic biomarker for NASH while further showing that ferroptosis is a therapeutic target for the disease.

Keywords

multi-omics / nonalcoholic steatohepatitis / simple steatosis / GDF3 / ferroptosis

References

[1] Younossi Z, Tacke F, Arrese M et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Hepatology 2019; 69: 2672- 82.

[2] Zhou J, Zhou F, Wang W et al. Epidemiological features of NAFLD from 1999 to 2018 in China Hepatology 2020; 71: 1851- 64.

[3] Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world Aliment Pharmacol Ther 2022; 56: 942- 56.

[4] Friedman SL, Neuschwander-Tetri BA, Rinella M et al. Mechanisms of NAFLD development and therapeutic strategies Nat Med 2018; 24: 908- 22.

[5] Yu Y, Cai J, She Z et al. Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases Adv Sci (Weinh) 2018; 6: 1801585.

[6] Tilg H, Adolph TE, Dudek M et al. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity Nat Metab 2021; 3: 1596- 607.

[7] Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease Cell 2021; 184: 2537- 64.

[8] Sanyal AJ, Shankar SS, Calle RA et al. Non-invasive biomarkers of nonalcoholic steatohepatitis: the FNIH NIMBLE project Nat Med 2022; 28: 430- 2.

[9] Ferguson D, Finck BN, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus Nat Rev Endocrinol 2021; 17: 484- 95.

[10] Canfora EE, Meex RCR, Venema K et al. Gut microbial metabolites in obesity, NAFLD and T2DM Nat Rev Endocrinol 2019; 15: 261- 73.

[11] Ji AL, Rubin AJ, Thrane K et al. Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma Cell 2020; 182: 497- 514.e22.

[12] Löffler MW, Mohr C, Bichmann L et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma Genome Med 2019; 11: 28.

[13] Xiao Y, Ma D, Zhao S et al. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer Clin Cancer Res 2019; 25: 5002- 14.

[14] Tabula Muris Consortium. A single-cell transcriptomic atlas characterizes ageing tissues in the mouse Nature 2020; 583: 590- 5.

[15] Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years Nat Rev Genet 2019; 20: 631- 56.

[16] Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry Cancer Discov 2013; 3: 1113- 21.

[17] Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition Nature 2014; 505: 344- 52.

[18] Altelaar AF, Munoz J, Heck AJ. Next-generation proteomics: towards an integrative view of proteome dynamics Nat Rev Genet 2013; 14: 35- 48.

[19] Wang J, Mauvoisin D, Martin E et al. Nuclear proteomics uncovers diurnal regulatory landscapes in mouse liver Cell Metab 2017; 25: 102- 17.

[20] Zhu R, Baker SS, Moylan CA et al. Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers J Pathol 2016; 238: 531- 42.

[21] Suppli MP, Rigbolt KTG, Veidal SS et al. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals Am J Physiol Gastrointest Liver Physiol 2019; 316: G462- 72.

[22] Baselli GA, Dongiovanni P, Rametta R et al. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker Gut 2020; 69: 1855- 66.

[23] Krahmer N, Najafi B, Schueder F et al. Organellar proteomics and phospho-proteomics reveal subcellular reorganization in diet-induced hepatic steatosis Dev Cell 2018; 47: 205- 21.e7.

[24] Yuan X, Sun Y, Cheng Q et al. Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease J Proteomics 2020; 221: 103683.

[25] Musso G, Cassader M, Paschetta E et al. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis Gastroenterology 2018; 155: 282- 302.e8.

[26] Mesnage R, Biserni M, Balu S et al. Integrated transcriptomics and metabolomics reveal signatures of lipid metabolism dysregulation in HepaRG liver cells exposed to PCB 126 Arch Toxicol 2018; 92: 2533- 47.

[27] Gosis BS, Wada S, Thorsheim C et al. Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1 Science 2022; 376: eabf8271.

[28] Liu B, Xiang L, Ji J et al. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2 J Clin Invest 2021; 131: e144801.

[29] Priest C, Tontonoz P. Inter-organ cross-talk in metabolic syndrome Nat Metab 2019; 1: 1177- 88.

[30] Kucukoglu O, Sowa JP, Mazzolini GD et al. Hepatokines and adipokines in NASH-related hepatocellular carcinoma J Hepatol 2021; 74: 442- 57.

[31] Vacca M, Leslie J, Virtue S et al. Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis Nat Metab 2020; 2: 514- 31.

[32] Xu G, Wang YM, Ying MM et al. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis Clin Mol Hepatol 2021; 27: 329- 45.

[33] Platko K, Lebeau PF, Byun JH et al. GDF10 blocks hepatic PPARγ activation to protect against diet-induced liver injury Mol Metab 2019; 27: 62- 74.

[34] Zhang Z, Xu X, Tian W et al. ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation J Hepatol 2020; 72: 976- 89.

[35] Hall JA, Ramachandran D, Roh HC et al. Obesity-linked PPARγ S273 phosphorylation promotes insulin resistance through growth differentiation factor 3 Cell Metab 2020; 32: 665- 675.e6.

[36] Xiong X, Kuang H, Ansari S et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis Mol Cell 2019; 75: 644- 660.e5.

[37] Khoshnevis S, Dreggors RE, Hoffmann TFR et al. A conserved Bcd1 interaction essential for box C/D snoRNP biogenesis J Biol Chem 2019; 294: 18360- 71.

[38] Haider S, Pal R. Integrated analysis of transcriptomic and proteomic data Curr Genomics 2013; 14: 91- 110.

[39] Schenk S, Bannister SC, Sedlazeck FJ et al. Combined transcriptome and proteome profiling reveals specific molecular brain signatures for sex, maturation and circalunar clock phase Elife 2019; 8: e41556.

[40] Meex RC, Hoy AJ, Morris A et al. Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism Cell Metab 2015; 22: 1078- 89.

[41] Yao S, Yang X, An J et al. Role of the S100 protein family in liver disease (Review) Int J Mol Med 2021; 48: 166.

[42] Stockwell BR, Friedmann Angeli JP, Bayir H et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease Cell 2017; 171: 273- 85.

[43] Guo Q, Furuta K, Lucien F et al. Integrin β1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH J Hepatol 2019; 71: 1193- 205.

[44] Widjaja AA, Singh BK, Adami E et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis Gastroenterology 2019; 157: 777- 792.e14.

[45] Seidman JS, Troutman TD, Sakai M et al. Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis Immunity 2020; 52: 1057- 1074.e7.

[46] Tsuchida T, Lee YA, Fujiwara N et al. A simple diet-and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer J Hepatol 2018; 69: 385- 95.

[47] Wang X, He Y, Mackowiak B et al. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases Gut 2021; 70: 784- 95.

[48] Schuster S, Cabrera D, Arrese M et al. Triggering and resolution of inflammation in NASH Nat Rev Gastroenterol Hepatol 2018; 15: 349- 64.

[49] Ye D, Yang K, Zang S et al. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil−macrophage crosstalk via the induction of CXCR2 J Hepatol 2016; 65: 988- 97.

[50] Pihlajamäki J, Kuulasmaa T, Kaminska D et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans J Hepatol 2012; 56: 663- 70.

[51] Lu Y, Liu X, Jiao Y et al. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα J Clin Invest 2014; 124: 3501- 13.

[52] Li Y, Wu S, Xiong S et al. Deficiency of periostin protects mice against methionine-choline-deficient diet−induced non−alcoholic steatohepatitis J Hepatol 2015; 62: 495- 7.

[53] Indira Chandran V, Wernberg CW, Lauridsen MM et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness Hepatology 2023; 77: 558- 72.

[54] Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer Cancer Cell 2019; 35: 830- 49.

[55] Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: a matter of life and death Nat Rev Gastroenterol Hepatol 2018; 15: 738- 52.

[56] Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy Nat Rev Clin Oncol 2020; 17: 395- 417.

[57] Guil S, Esteller M, Esteller M. RNA-RNA interactions in gene regulation: the coding and noncoding players Trends Biochem Sci 2015; 40: 248- 56.

[58] Hwang S, He Y, Xiang X et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets Hepatology 2020; 72: 412- 29.

[59] Chen W, Zhang J, Fan HN et al. Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease Therap Adv Gastroenterol 2018; 11: 1756284818815184.

[60] Mazzocca A, Carloni V, Sciammetta S et al. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration J Hepatol 2002; 37: 322- 30.

RIGHTS & PERMISSIONS

The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.